Integrase inhibitors: a clinical review of raltegravir and elvitegravir

J HIV Ther. 2008 Jun;13(2):36-9.

Authors

Philip Grant¹, Andrew Zolopa

Affiliation

¹ Division of Infectious Diseases and Geographic Medicine, Stanford University, Stanford, CA 94305-5107, USA. pmgrant@stanford.edu

PMID: 18953272

No abstract available

Publication types

Review

MeSH terms

Clinical Trials, Phase III as Topic
Dose-Response Relationship, Drug
Drug Interactions
Drug Resistance, Viral / genetics
Drug Therapy, Combination
HIV / drug effects*
HIV / enzymology
HIV Infections / drug therapy*
HIV Integrase / drug effects
HIV Protease Inhibitors / adverse effects
HIV Protease Inhibitors / pharmacokinetics
HIV Protease Inhibitors / therapeutic use*
Humans
Pyrrolidinones / adverse effects
Pyrrolidinones / pharmacokinetics
Pyrrolidinones / therapeutic use*
Quinolones / adverse effects
Quinolones / pharmacokinetics
Quinolones / therapeutic use*
Raltegravir Potassium

Substances

HIV Protease Inhibitors
Pyrrolidinones
Quinolones
Raltegravir Potassium
elvitegravir
HIV Integrase